The US Food and Drug Administration (FDA) has approved IntelGenxs’ anti-depressant CPI-300 to treat patients with major depressive disorder.

CPI-300 is a single dose 450mg formulation of bupropion hydrochloride.

IntelGenx president and CEO Horst Zerbe said that physicians would embrace CPI-300 as a safe alternative for patients requiring high-dose anti-depressant therapy.

”So we now turn our focus towards the commercialisation of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012," Zerbe added.